Atlas Trials

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Clinical trial NCT05060003 · TERMINATED

Trial details

NCT number
NCT05060003
Sponsor
Washington University School of Medicine
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Stage II Melanoma
Start date
2022-11-08
Primary completion
2023-11-27
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.